Ethambutol
- Generic Name
- Ethambutol
- Brand Names
- Etibi, Myambutol
- Drug Type
- Small Molecule
- Chemical Formula
- C10H24N2O2
- CAS Number
- 74-55-5
- Unique Ingredient Identifier
- 8G167061QZ
- Background
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.
...
- Indication
Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.
- Associated Conditions
- Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium Infections, Pulmonary Tuberculosis (TB)
- Associated Therapies
- -
Shortened Regimen for Drug-susceptible TB in Children
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 860
- Registration Number
- NCT06253715
- Locations
- 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳Dr. D.Y. Patil Medical College, Hospital and Research Center, Pimpri, Pune, India
🇮🇩Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-13
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇺🇬
12401, Joint Clinical Research Centre (JCRC)/Kampala CRS, Kampala, Uganda
🇲🇼30301, Blantyre CRS, Blantyre, Malawi
🇲🇼12001, Malawi CRS, Lilongwe, Malawi
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳Harbin Chest Hospital, Harbin, Heilongjiang, China
A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT05966688
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
- Conditions
- Interventions
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Tuberculosis Research Centre, India
- Target Recruit Count
- 550
- Registration Number
- NCT05047055
- Locations
- 🇮🇳
National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 112
- Registration Number
- NCT04930744
- Locations
- 🇿🇦
Isango Lethemba TB Research Unit, Port Elizabeth, South Africa
🇿🇦Tembisa Clinical Research Centre-The Aurum Institute, Johannesburg, Gauteng, South Africa
Hypertonic Saline for MAC
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 50
- Registration Number
- NCT04921943
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇨🇦University Health Network, Toronto, Ontario, Canada
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.